Who Owns CG Oncology Stock?
NASDAQ: CGONHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 111.67%
- Institutions (% of float)
- 111.92%
- Held by insiders
- 0.23%
- Institutional holders
- 342
- Institutions 99.8%
- Insiders 0.2%
- Public and other 0.0%
Who owns CG Oncology stock?
Institutional investors own about 111.7% of CG Oncology's shares, spread across 342 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.23% of CGON.
The largest institutional holders are RTW Investments LP (9.53%), T. Rowe Price Investment Management, Inc. (7.53%) and Decheng Capital LLC (7.13%). Together, the top 10 institutions control 57.6% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their CGON positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CGON
| Institution | Shares | % Held | Change |
|---|---|---|---|
| RTW Investments LP | 8.51M | 9.53% | 0.0% |
| T. Rowe Price Investment Management, Inc. | 6.73M | 7.53% | +1.7% |
| Decheng Capital LLC | 6.37M | 7.13% | 0.0% |
| Blackrock Inc. | 6.35M | 7.11% | +1.5% |
| Wellington Management Group, LLP | 4.92M | 5.51% | -7.7% |
| FMR, LLC | 4.59M | 5.14% | +10.4% |
| TCG Crossover Management, LLC | 3.67M | 4.11% | 0.0% |
| Vanguard Capital Management LLC | 3.57M | 4.00% | +7.8% |
| Vanguard Portfolio Management LLC | 3.52M | 3.94% | +1.5% |
| State Street Corporation | 3.23M | 3.62% | -5.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CGON
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.86M | 3.20% |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.57M | 2.88% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.38M | 2.67% |
| iShares Trust-iShares Russell 2000 ETF | 1.91M | 2.14% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 1.72M | 1.93% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.54M | 1.73% |
| T. Rowe Price New Horizons Fund, Inc. | 1.11M | 1.25% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 860.03K | 0.96% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 808.01K | 0.90% |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 797.44K | 0.89% |
Frequently asked questions
Who is the largest shareholder of CG Oncology?
RTW Investments LP is the largest institutional shareholder of CGON, owning 9.53% of shares outstanding (8.51M shares) as of its latest 13F filing.
What percentage of CG Oncology is owned by institutions?
Institutions own about 111.7% of CGON shares and 111.9% of the public float.
How much of CG Oncology do insiders own?
Insiders, such as officers and directors, own about 0.23% of CGON shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.